A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review

Jingyi Yang,1– 3,* Qian Shen,1,4,* Xiaoyan Ke,5 Wei Liu,1,3 Ping Yang5 1Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People’s Republic of China; 2Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences, Peking Univer...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang J, Shen Q, Ke X, Liu W, Yang P
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:Clinical Pharmacology: Advances and Applications
Subjects:
Online Access:https://www.dovepress.com/a-case-report-of-sustained-cytokine-release-syndrome-due-to-glofitamab-peer-reviewed-fulltext-article-CPAA
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849697687552655360
author Yang J
Shen Q
Ke X
Liu W
Yang P
author_facet Yang J
Shen Q
Ke X
Liu W
Yang P
author_sort Yang J
collection DOAJ
description Jingyi Yang,1– 3,* Qian Shen,1,4,* Xiaoyan Ke,5 Wei Liu,1,3 Ping Yang5 1Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People’s Republic of China; 2Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of China; 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, People’s Republic of China; 4The second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710004, People’s Republic of China; 5Department of Hematology, Peking University Third Hospital, Beijing, 100191, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wei Liu, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People’s Republic of China, Email liuwei0023@bjmu.edu.cn Ping Yang, Department of Hematology, Peking University Third Hospital, Beijing, 100191, People’s Republic of China, Tel +8610-13488693764, Email yangping198302@163.comAbstract: Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.Keywords: glofitamab, cytokine release syndrome, cytokines, interleukin-6
format Article
id doaj-art-dca7410c78d14b2899ffdebd50df9b9c
institution DOAJ
issn 1179-1438
language English
publishDate 2025-04-01
publisher Dove Medical Press
record_format Article
series Clinical Pharmacology: Advances and Applications
spelling doaj-art-dca7410c78d14b2899ffdebd50df9b9c2025-08-20T03:19:07ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382025-04-01Volume 177983102518A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature ReviewYang JShen QKe XLiu WYang PJingyi Yang,1– 3,* Qian Shen,1,4,* Xiaoyan Ke,5 Wei Liu,1,3 Ping Yang5 1Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People’s Republic of China; 2Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People’s Republic of China; 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 100191, People’s Republic of China; 4The second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, 710004, People’s Republic of China; 5Department of Hematology, Peking University Third Hospital, Beijing, 100191, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wei Liu, Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, People’s Republic of China, Email liuwei0023@bjmu.edu.cn Ping Yang, Department of Hematology, Peking University Third Hospital, Beijing, 100191, People’s Republic of China, Tel +8610-13488693764, Email yangping198302@163.comAbstract: Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.Keywords: glofitamab, cytokine release syndrome, cytokines, interleukin-6https://www.dovepress.com/a-case-report-of-sustained-cytokine-release-syndrome-due-to-glofitamab-peer-reviewed-fulltext-article-CPAAglofitamabcytokine release syndromecytokinesinterleukin-6
spellingShingle Yang J
Shen Q
Ke X
Liu W
Yang P
A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
Clinical Pharmacology: Advances and Applications
glofitamab
cytokine release syndrome
cytokines
interleukin-6
title A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
title_full A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
title_fullStr A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
title_full_unstemmed A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
title_short A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review
title_sort case report of sustained cytokine release syndrome due to glofitamab and literature review
topic glofitamab
cytokine release syndrome
cytokines
interleukin-6
url https://www.dovepress.com/a-case-report-of-sustained-cytokine-release-syndrome-due-to-glofitamab-peer-reviewed-fulltext-article-CPAA
work_keys_str_mv AT yangj acasereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT shenq acasereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT kex acasereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT liuw acasereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT yangp acasereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT yangj casereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT shenq casereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT kex casereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT liuw casereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview
AT yangp casereportofsustainedcytokinereleasesyndromeduetoglofitamabandliteraturereview